Title: Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial

Authors: Szakacs, Zoltan et al.

 

What You Need to Know:

Treatment with pitolisant, a first-in-class, highly-selective, histamine H3 receptor inverse agonist, significantly reduced cataplexy in patients with severe nacrolepsy. Pitolisant reduced the frequency of attacks per week and significantly improved excessive daytime sleepiness (EDS).


Continue Reading

Trial Design:

  • HARMONY CTP was a Phase 3, multicenter, randomized, prospective, double blind, placebo-controlled study evaluating the efficacy and safety of pitolisant (5mg–40mg individual dose titration) vs. placebo 
  • Study period: April 19, 2013 to January 28, 2015 
  • 105 patients; pitolisant (n=54) and placebo (n=51) 
  • Enrolled patients had a high frequency of cataplexy (7–9 attacks per week), a high level of diurnal somnolence, or associated symptoms like hallucinations 
  • The primary endpoint was the change in the average number of cataplexy attacks per week as recorded in patient diaries between the 2 weeks of baseline and the 4 weeks of stable dosing period

Key Outcomes:

  • Pitolisant significantly reduced cataplexy when given once daily for 2 months in severely affected patients
  • Frequency of attacks per week decreased by 75% (from 9.15 to 2.27) with pitolisant vs. 38% (from 7.31 to 4.52) with placebo (P<0.0001)
  • Excessive Daytime Sleepiness (EDS) was also significantly improved with pitolisant therapy, as well as hallucinations and patient’s quality of life
  • Most frequent side effects: headache, nausea, and anxiety, irritability